Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Quadriplex model enhances urine-based detection of prostate cancer.

Jamaspishvili T, Kral M, Khomeriki I, Vyhnankova V, Mgebrishvili G, Student V, Kolar Z, Bouchal J.

Prostate Cancer Prostatic Dis. 2011 Dec;14(4):354-60. doi: 10.1038/pcan.2011.32. Epub 2011 Jul 26.

PMID:
21788966
2.

A three-gene panel on urine increases PSA specificity in the detection of prostate cancer.

Rigau M, Ortega I, Mir MC, Ballesteros C, Garcia M, Llauradó M, Colás E, Pedrola N, Montes M, Sequeiros T, Ertekin T, Majem B, Planas J, Ruiz A, Abal M, Sánchez A, Morote J, Reventós J, Doll A.

Prostate. 2011 Dec;71(16):1736-45. doi: 10.1002/pros.21390. Epub 2011 Apr 25.

PMID:
21520154
3.

PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.

Rigau M, Morote J, Mir MC, Ballesteros C, Ortega I, Sanchez A, Colás E, Garcia M, Ruiz A, Abal M, Planas J, Reventós J, Doll A.

Prostate. 2010 Dec 1;70(16):1760-7. doi: 10.1002/pros.21211.

PMID:
20672322
4.

A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer.

Cao DL, Ye DW, Zhang HL, Zhu Y, Wang YX, Yao XD.

Prostate. 2011 May 15;71(7):700-10. doi: 10.1002/pros.21286. Epub 2010 Oct 18.

PMID:
20957673
5.

The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population.

Shen M, Chen W, Yu K, Chen Z, Zhou W, Lin X, Weng Z, Li C, Wu X, Tao Z.

Exp Mol Pathol. 2011 Feb;90(1):97-100. doi: 10.1016/j.yexmp.2010.10.009. Epub 2010 Oct 20.

PMID:
20970419
6.

PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.

Ramos CG, Valdevenito R, Vergara I, Anabalon P, Sanchez C, Fulla J.

Urol Oncol. 2013 Nov;31(8):1522-6. doi: 10.1016/j.urolonc.2012.05.002. Epub 2012 Jun 9.

PMID:
22687565
7.

Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients.

Zehentner BK, Secrist H, Zhang X, Hayes DC, Ostenson R, Goodman G, Xu J, Kiviat M, Kiviat N, Persing DH, Houghton RL.

Mol Diagn Ther. 2006;10(6):397-403.

PMID:
17154657
8.

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H.

Eur Urol. 2011 Nov;60(5):1045-54. doi: 10.1016/j.eururo.2011.08.003. Epub 2011 Aug 25. Review.

PMID:
21871709
9.
10.

A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer.

Ouyang B, Bracken B, Burke B, Chung E, Liang J, Ho SM.

J Urol. 2009 Jun;181(6):2508-13; discussion 2513-4. doi: 10.1016/j.juro.2009.01.110. Epub 2009 Apr 16.

11.

Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer.

Roberts MJ, Chow CW, Schirra HJ, Richards R, Buck M, Selth LA, Doi SA, Samaratunga H, Perry-Keene J, Payton D, Yaxley J, Lavin MF, Gardiner RA.

Prostate. 2015 Apr 1;75(5):539-49. doi: 10.1002/pros.22942. Epub 2015 Jan 18.

PMID:
25597828
12.

Emerging biomarkers for the diagnosis and prognosis of prostate cancer.

Sardana G, Dowell B, Diamandis EP.

Clin Chem. 2008 Dec;54(12):1951-60. doi: 10.1373/clinchem.2008.110668. Epub 2008 Oct 16. Review.

13.

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.

Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J.

Urology. 2007 Mar;69(3):532-5.

PMID:
17382159
14.

Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.

Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA, Chinnaiyan AM.

J Natl Cancer Inst. 2004 Jun 2;96(11):834-43. Erratum in: J Natl Cancer Inst. 2004 Jul 21;96(14):1112.

PMID:
15173267
15.

The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer.

Mearini E, Antognelli C, Del Buono C, Cochetti G, Giannantoni A, Nardelli E, Talesa VN.

Biomarkers. 2009 Jun;14(4):235-43. doi: 10.1080/13547500902807306.

PMID:
19489685
16.

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J.

J Urol. 2008 Apr;179(4):1587-92. doi: 10.1016/j.juro.2007.11.038. Epub 2008 Mar 4.

PMID:
18295257
17.

PCA3: from basic molecular science to the clinical lab.

Day JR, Jost M, Reynolds MA, Groskopf J, Rittenhouse H.

Cancer Lett. 2011 Feb 1;301(1):1-6. doi: 10.1016/j.canlet.2010.10.019. Epub 2010 Nov 18. Review.

PMID:
21093148
18.

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H.

Clin Chem. 2006 Jun;52(6):1089-95. Epub 2006 Apr 20.

19.

Urine markers in monitoring for prostate cancer.

Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z, Bouchal J.

Prostate Cancer Prostatic Dis. 2010 Mar;13(1):12-9. doi: 10.1038/pcan.2009.31. Epub 2009 Aug 4. Review.

PMID:
19652665
20.

The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.

van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, Witjes JA, Cornel EB, Karthaus HF, Smits GA, Dijkman GA, Mulders PF, Schalken JA.

Clin Cancer Res. 2007 Feb 1;13(3):939-43.

Supplemental Content

Support Center